Diabetes drug tested as potential lifesaver in deadly sepsis
NCT ID NCT07206160
Summary
This study aims to see if dapagliflozin, a drug typically used for diabetes, can reduce harmful inflammation in patients with sepsis, a life-threatening body-wide infection. Researchers will give the drug or a placebo to 64 adults in the ICU and measure specific markers in the blood to see if it improves organ function and reduces the risk of death. The main goal is to understand if reducing inflammation with this drug can help control the disease and lead to better outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.